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Aim: The aberrant expression of regenerating islet-derived family member, 4 (Reg IV) has been found in various
human cancers. However, the roles of Reg IV gene and its encoding product in human glioma have not been
clearly understood. Therefore, the aim of this study was to investigate the clinicopathological significance of Reg IV
expression in glioma.
Methods: Reg IV mRNA and protein expression in human gliomas and non-neoplastic brain tissues were
respectively detected by real-time quantitative RT-PCR assay, Western blot, and immunohistochemistry. The
association of Reg IV immunostaining with clinicopathological factors and prognosis of glioma patients was also
statistically analyzed.
Results: Reg IV mRNA and protein expression levels in glioma tissues were both significantly higher than those in
the corresponding non-neoplastic brain tissues (both P< 0.001). Additionally, the increased Reg IV immunostaining
in glioma tissues was significantly associated with advanced pathological grade (P = 0.008). Reg IV protein up-
regulation was also significantly correlated with low Karnofsky performance score (KPS) (P = 0.02). Moreover, the
overall survival of patients with high Reg IV protein expression was dramatically shorter than those with low Reg IV
protein expression (P< 0.001). Multivariate Cox regression analysis further confirmed that Reg IV expression was an
independent prognostic factor for patients with gliomas (P = 0.008).
Conclusions: These convinced evidences suggest for the first time that Reg IV might accelerate disease
progression and act as a candidate prognostic marker for gliomas.
Virtual slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/2145344361720706
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PrognosisIntroduction
Human glioma represents the most common malignancy
in central nervous system for both children and adults.
According to the World Health Organization (WHO)
classification, gliomas are divided into well-differentiated
low grade astrocytomas [WHO grade I ~ II], anaplastic
astrocytomas (WHO grade III) and glioblastoma multi-
forme (GBM, WHO grade IV) [1], which especially* Correspondence: zhangys_td@163.com; tu.fmmu@gmail.com
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reproduction in any medium, provided the orrepresents the most aggressive and the most lethal type
of brain tumor. In recent years, there have been great
progress occurred in therapeutic technologies, such as
surgery, radiotherapy, photodynamic therapy [2,3], and
chemotherapy; however, the clinical outcome of glioma
patients remains poor, with an average patient life expect-
ancy of only 15 months after diagnosis for GBM patients
[4]. The reason for this unfavorable prognosis is that
tumor cells in GBM tissues are not only highly prolifera-
tive but also readily invade surrounding brain structures,
thereby making complete surgical resection practically
impossible. Hence, molecular characteristics responsible
for the tumor invasion process and the suboptimaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological features of 128 patients with
gliomas
Features WHO I WHO II WHO III WHO IV
Case No. 18 14 38 58
Mean age (year) 38.6 45.9 43.1 44.2
Gender
Male 12 6 25 33
Female 6 8 13 25
KPS
>80 15 11 9 15
<80 3 3 29 43
Surgery
Gross total resection 18 14 28 38
Partial resection 0 0 9 15
Biopsy 0 0 1 5
Adjuvant treatment
Radiotherapy 0 0 30 12
Chemotherapy 0 1 0 6
Radiotherapy and Chemotherapy
combination
0 0 5 28
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tic and therapeutic markers for human gliomas.
Human regenerating (Reg) genes, initially identified
from regenerating rat pancreatic islets, encode five small-
secreted proteins (Reg Iα, Reg Iβ, Reg IIIα, Reg IIIβ and
Reg IV) with similar structure to the proteins of the
calcium-dependent lectin (C-type lectin) superfamily [5].
Reg proteins act as inflammation-modifying acute phase
reactants and mucosal repair stimulating factors in the
gastrointestinal tract, growth factors and anti-apoptotic
survival signal mediators for pancreatic islet cells and
neurons [6]. As the most recently discovered member of
the human Reg family proteins, Reg IV has been demon-
strated to enhance cell proliferation and inhibit apoptosis
by inducing phosphorylation of epidermal growth factor
receptor (EGFR) (Tyr992, Tyr1068) and Akt (Thr308,
Ser473) [7]. In normal human body, the expression of
Reg IV mRNA is restricted to gastrointestinal tract, pan-
creas, prostate, and testes [8]. Normal parietal cells in
stomach stain for Reg IV, whereas goblet cells of the ven-
tricular mucosa in areas displaying intestinal metaplasia
and in Barrett’s esophagus showed robust accumulation
of Reg IV [9]. In normal intestinal mucosa, goblet cells
show a weak Reg IV staining, while the mucosa in inflam-
matory bowel disease is strong Reg IV positive [9]. The
aberrant expression of Reg IV has been found in various
human cancers, including gastric cancer, colorectal can-
cer, ductal cancer of the pancreas, gallbladder carcin-
oma, prostate cancer, and adenoid cystic carcinoma in
the salivary gland [10-15]. Recent studies also suggested
that Reg IV may play an important role in initiating
tumorigenesis, and its detection might be useful in the
early diagnosis of tumor formation. However, the role
of Reg IV gene and its encoding product in human gli-
oma has not been clearly understood. To address this
problem, Reg IV expression at mRNA and protein levels
in human glioma and non-neoplastic brain tissues were
respectively measured by real-time quantitative RT-PCR
assay, Western blot, and immunohistochemistry. The
association of Reg IV immunostaining with clinico-
pathological factors or prognosis of glioma patients was
also statistically analyzed.
Materials and methods
Patients and tissue samples
This study was approved by the Research Ethics Com-
mittee of Tangdu Hospital, Fourth Military Medical Uni-
versity, P. R. China. Written informed consent was
obtained from all of the patients. All specimens were
handled and made anonymous according to the ethical
and legal standards.
A total of 128 formalin-fixed, paraffin-embedded spe-
cimens of gliomas resected between 2000 and 2010 were
retrieved from the archives of the Pathology Departmentof Tangdu Hospital, Fourth Military Medical University,
P. R. China. All the slides were re-evaluated according to
WHO classifications [1] by two pathologists, with differ-
ences resolved by careful discussion. A total of 76 males
and 52 females (1.46:1) were enrolled in this study, and
the median age was 42 years (range, 12–71). Thirty-two
of the 128 gliomas were classified as low-grade [18 pilo-
cytic astrocytomas (WHO I) and 14 diffuse astrocytomas
(WHO II)], and 96 were classified as high-grade gliomas
[38 anaplasia astrocytomas (WHO III), and 58 primary
glioblastomas (WHO IV)]. None of the patients had
received chemotherapy or radiotherapy prior to surgery.
The clinicopathological features and the treatment strat-
egies of all the patients were indicated in Table 1. Paraffin
and snap-frozen sections of non-neoplastic brain tissues
from 10 patients with intractable epilepsy were also
included as controls. Five years follow-up was performed,
and all patients had complete follow-up until death.
Overall survival time was calculated from the date of the
initial surgical operation to death. Patients, who died of
diseases not directly related to their gliomas or due to
unexpected events, were excluded from this study. In
addition, 20 glioma specimens [5 pilocytic astrocytomas
(WHO I), 3 diffuse astrocytomas (WHO II), 3 anaplasia
astrocytomas (WHO III), and 9 primary glioblastomas
(WHO IV)] were snap-frozen in liquid nitrogen and
stored at −80°C following surgery for real-time quantita-
tive RT-PCR assay and western blot analysis.
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The mRNA expression of Reg IV in glioma and non-
neoplastic brain tissues was detected by real-time quan-
titative RT-PCR analysis according to the conventional
protocols of Tangdu hospital [16]. Especially, the primers
were designed as follows: for human Reg IV, forward pri-
mer, 5'- TGC ACG ACC CAC AGA AGA G -3', and re-
verse primer, 5'- GAC TTG CCA GAC CAG GAT CT -3';
for human glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), forward primer, 5'- CCC ACT CCT CCA CCT
TTG AC-3', and reverse primer, 5'-ATG AGG TCC ACC
ACC CTG TT-3'. Each sample was examined in tripli-
cate and the amounts of the PCR products produced
were non-neoplasticized to GAPDH which served as in-
ternal control.
Western blot analysis
The protein expression of Reg IV in glioma and non-
neoplastic brain tissues was detected by Western blot
analysis according to the conventional protocols of
Tangdu hospital [16-18]. Briefly, the tissues were har-
vested by scraping and lysed using modified radioimmu-
noprecipitation assay buffer (50 mM Tris–HCl, pH 7.4),
1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl,
1 mM ethylenediaminetetraacetic acid (EDTA), protease
inhibitor cocktail complete. The protein content was
determined according to Bradford’s method, with bovine
serum albumin used as a standard. Equal amounts of
protein were separated electrophoretically on 7.5% SDS-
polyacrylamide gels and transferred onto polyvinylidene
difluoride membranes (Roche; Basel, Switzerland). The
membranes were probed with a goat anti-human Reg IV
polyclonal antibody (1:25, R&D Systems, Abingdon, UK).
The expression level of Reg IV was determined by incu-
bating the membranes with horseradish peroxidase-
conjugated anti-goat immunoglobulin G (1:1000 dilu-
tion) and enhanced chemiluminescence reagent (Pierce;
Minneapolis, MN, USA), according to the manufac-
turers’ suggested protocols. The membranes were
stripped and reprobed with an anti-β-actin mouse mono-
clonal antibody (1:1000 dilution: Sigma; St Louis, MO,
USA) as a loading control. Densitometry was performed
using ImageJ software (http://rsb.info.nih.gov/ij/) from
National Institutes of Health (NIH; Bethesda, MD, USA).
We evaluated the expression of Reg IV as an optical
densitometry (OD) ratio that was scored as the densi-
tometry of Reg IV relative to the densitometry of β-actin.
Immunohistochemistry assay
The immunostaining of Reg IV protein in glioma and
non-neoplastic brain tissues was detected by Immuno-
histochemistry assay according to the conventional pro-
tocols of Tangdu hospital [16-18]. Briefly, specimens
were blocked with phosphate-buffered saline (PBS)containing 5% normal horse serum (Vector Laboratories
Inc., Burlingame, CA, USA) following peroxidase block-
ing with 0.3% H2O2/methanol for 30 min. All incubations
with goat anti-human Reg IV polyclonal antibody (1:25,
R&D Systems, Abingdon, UK) were carried out overnight
at 4°C. Then the specimens were briefly washed in PBS
and incubated at room temperature with the anti-goat
antibody and avidin-biotin peroxidase (Vector Laborator-
ies Inc., Burlingame, CA, USA). The specimens were then
washed in PBS and color-developed by diaminobenzidine
solution (Dako Corporation, Carpinteria, CA, USA). After
washing with water, specimens were counterstained with
Meyer’s hematoxylin (Sigma Chemical Co., St Louis, MO,
USA). Non-neoplastic brain tissues were used as control
tissues and non-immune IgG was also used as negative
control antibody for immunohistochemical staining. The
immunohistochemical reaction was performed simultan-
eously for all slides.
Assessment of immunohistochemical staining was
evaluated by two independent pathologists. The scores
of the two pathologists were compared and any discrep-
ant scores were trained through re-examining the stain-
ings by both pathologists to achieve a consensus score.
The number of Reg IV positive-staining cells showing
immunoreactivity in ten representative microscopic fields
was counted and the percentage of positive cells was cal-
culated. The percentage scoring of immunoreactive
tumor cells was as follows: 0 (0%), 1 (1-10%), 2 (11-50%)
and 3 (>50%). The staining intensity was visually scored
and stratified as follows: 0 (negative), 1 (weak), 2 (moder-
ate) and 3 (strong). A final immunoreactivity scores (IRS)
was obtained for each case by multiplying the percentage
and the intensity score. The median of IRS for all exam-
ined samples was 5.3. Thus, the Reg IV protein expres-
sion levels were further analyzed by classifying IRS values
as low (based on a IRS value less than 5.3) and as high
(based on a IRS value greater than 5.3).Statistical analysis
All computations were carried out using the software of
SPSS version13.0 for Windows (SPSS Inc, IL, USA). Data
were expressed as means ± standard deviation (SD). The
analysis of variance (ANOVA) was used to determine
the statistical differences among the groups. Spearman
rank correlation is used to analyze the correlation be-
tween Reg IV mRNA expression and Reg IV protein ex-
pression. A life table was calculated according to the
Kaplan-Meier method. Hazard ratios for the time-to-
event endpoint were estimated using the multivariate
Cox regression analysis in a forward stepwise method to
evaluate the effect of multiple independent prognostic
factors on survival outcome. Differences were consid-
ered statistically significant when p was less than 0.05.
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Reg IV mRNA and protein expression in human glioma
tissues
The expression levels of Reg IV mRNA were detected in
20 glioma and 10 non-neoplastic brain tissues normal-
ized to GAPDH. As shown in Figure 1A and C, the ex-
pression levels of Reg IV mRNA were found to be
distinctly increased in glioma tissues compared to non-
neoplastic brain tissues, corresponding to the glioma
WHO grades. The statistic results showed that its ex-
pression in high-grade (III: 2.4 ± 0.1; IV: 2.0 ± 0.09) andFigure 1 Reg IV mRNA and protein expression in 20 glioma tissues in
respectively detected by real-time quantitative RT-PCR assay and We
tissues with different grades and non-neoplastic brain tissues. (B) Expressio
non-neoplastic brain tissues. (C) A graphical representation of the Reg IV m
the Reg IV protein level expression profiles in (B). 'N' refers to non-neoplast
refers to glioma tissues with grade III ~ IV. *P< 0.01, compared with ‘N’; ‘**’Plow-grade (I: 1.5 ± 0.03; II: 1.7 ± 0.07) gliomas were both
significantly higher than that in non-neoplastic brains
tissues (0.8 ± 0.03; Grade I vs. N: P = 0.003; Grade II vs.
N: P = 0.003; Grade III vs. N: P< 0.001; Grade IV vs. N:
P< 0.001; Figure 1C). Additionally, there was also a sig-
nificant increasing in mRNA copies of Reg IV corre-
sponding to the glioma WHO grades (P = 0.002). With
the agreement of above results, Western blot analysis
also found Reg IV protein expression was 2.3 ± 0.1,
1.6 ± 0.08, 1.4 ± 0.06, 1.2 ± 0.03, 0.6 ± 0.01 for glioma
grade IV, glioma grade III, glioma grade II, glioma gradedifferent grades and non-neoplastic brain tissues were
stern blot analysis. (A) Expression levels of Reg IV mRNA in glioma
n levels of Reg IV protein in glioma tissues with different grades and
RNA level expression profiles in (A). (D) A graphical representation of
ic brain tissues; 'I ~ II' refers to glioma tissues with grade I ~ II; 'III ~ IV'
< 0.001, compared with ‘N’.
Figure 2 Representative sections for Reg IV immunoreactivity in glioma tissues (A) and nonneoplastic brain tissues (B) (×400). Reg IV
was mainly expressed in the nuclei with brown yellow.
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Grade II vs. N: P = 0.004; Grade III vs. N: P< 0.001;
Grade IV vs. N: P< 0.001; Figure 1B, D). Notablely, the
Reg IV mRNA expression was closely correlated with its
protein expression (r = 0.7; P = 0.01).Table 2 Association of Reg IV expression in human





Reg IV expression P
High (n, %) Low (n, %)
WHO grade
I 18 8 (44.4) 10 (55.6) 0.008
II 14 8 (57.1) 6 (42.9)
III 38 32 (84.2) 6 (15.8)
IV 58 58 (100.0) 0 (0)
Age
<55 52 42 (80.8) 10 (19.2) NS
≥55 76 64 (84.2) 12 (15.8)
Gender
Male 76 64 (84.2) 12 (15.8) NS
Female 52 42 (80.8) 10 (19.2)
KPS
<80 78 72 (92.3) 6 (7.7) 0.02
≥80 50 34 (68.0) 16 (32.0)Reg IV immunostaining and its association with
clinicopatholigcal features of gliomas
Reg IV protein expression and cellular localization were
also detected by immunohistochemistry assay in 128 gli-
oma specimens and 10 non-neoplastic brain tissues. In
all non-neoplastic brain tissues, no Reg IV positive stain-
ing was found (Figure 2A), whereas Reg IV positive
staining was localized in the nuclei of tumor cells in gli-
oma tissues (Figure 2B). The cellular localization of Reg
IV protein found in this study was consistent with the
previous studies of Oue et al. [12], HAYASHI et al. [13]
and Tamura et al. [14]. Of 128 glioma specimens, 106
(82.8%) highly expressed Reg IV. Then, we analyzed the
associations of Reg IV expression with various clinico-
pathological parameters of glioma tissues. Data in Table 2
showed that the high level of Reg IV expression was sig-
nificantly more common in glioma tissues with advanced
pathologic grade than those with low pathologic grade
(P = 0.008). Especially, the frequencies of Reg IV high ex-
pression in glioma tissues with high pathologic grades
were more than those with low pathologic grades (Grade
III: 84.2% vs. 15.8%, P< 0.001; Grade IV: 100.0% vs. 0,
P< 0.001). In addition, a significant relationship was also
found between Reg IV expression and the KPS. Increased
expression of Reg IV protein more frequently occurred
in tumors with low KPS than those with high KPS
(P = 0.02, Table 2). However, there was no significant as-
sociation between Reg IV expression and other clinico-
pathological parameters, including gender and age at
diagnosis (P> 0.05, Table 2).Prognostic value of reg IV expression in overall survival
of patients with gliomas
In order to investigate the prognostic value of Reg IV
expression in overall survival of patients with gliomas,
the detail clinical information of all 128 gliioma patients
in Reg IV-high or -low groups was reviewed. During the
follow-up period, 100 of 128 glioma patients (78.1%) had
died [90 (84.9%) from the Reg IV-high group and 10
(45.5%) from the Reg IV-low group]. We evaluated the
prognostic significance of Reg IV protein expression
levels in different subgroups of glioma patients stratified
according to the WHO grading. Notably, high Reg IV
expression also significantly correlated with shorter
overall survival time in subgroups of glioma patients
with grade III and grade IV (both P ≤ 0.001, Figure 3C
Figure 3 Kaplan-Meier survival curves for glioma patients in WHO grade I (A), grade II (B), grade III (C), grade IV (D), and all patients
(E) with high and low expression of Reg IV.
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in grades I and II subgroups had no significant differ-
ences between high Reg IV expression and low Reg IV
expression (P ≥ 0.05; Figure 3A and B). Moreover, as
determined by the log-rank test, the survival rate of all
glioma patients with high Reg IV expression was signifi-
cantly lower than those with low Reg IV expression
(P ≤ 0.001; Figure 3E).
In multivariate analysis, Cox proportional hazards
model involving the expression level of Reg IV protein
and various clinical parameters identified the high Reg
IV protein expression (P = 0.008) as an independent
prognostic factor for glioma patients. Statistical values of
the expression of Reg IV and other clinical parameters
derived from Cox stepwise proportional hazards model
were indicated in Table 3.
Discussion
Understanding of the molecular alterations that occur
during tumorigenesis, and identification of novel mar-
kers for cancer diagnosis and novel targets for treatment,
may be important for the improvements in tumor diag-
nosis, treatment and prevention. This study was focus
on human glioma, which is an aggressive tumor with
heterogeneous tumor biology, high invasiveness, rapid
tumor cell proliferation and poor prognosis. Several gen-
etic and molecular mechanisms of tumorigenesis in gli-






Age 0.9 0.6-1.7 0.7
Gender 1.0 0.7-1.8 0.3
KPS 2.0 1.3-3.0 0.1
Extent of resection 1.3 0.9-2.1 0.1
Type of adjuvant treatment 1.4 1.0-2.2 0.1
Reg IV expression 6.9 1.1-18.3 0.008this tumor progression remain unclear. As results of our
analysis, there are four points of findings. Firstly, Reg IV
was up-regulated in human glioma tissues compared
with non-neoplastic brain tissues at both mRNA and
protein levels; Secondly, the increased Reg IV expression
in glioma tissues was significantly correlated with
advanced tumor progression and aggressive clinico-
pathological features; Thirdly, the results of Kaplan-
Meier analyses shown that glioma tissues with high Reg
IV expression tend to have poorer overall survival. Fi-
nally, the multivariate analysis clearly demonstrated that
the high expression of Reg IV was a statistically signifi-
cant risk factor affecting overall survival in glioma
patients, suggesting that Reg IV expression could be a
valuable marker of glioma progression and prognosis.
To our knowledge, this is the first study to analyze the
expression patterns and clinical significance of Reg IV at
transcriptional and translational levels in a large number
of glioma patients.
Reg genes encode five multifunctional small-secreted
proteins, which can act as acute phase reactants, lectins,
or antiapoptotic or growth agents [19]. As a novel mem-
ber of the Reg family, human Reg IV is mapped to
chromosome 1q12-q21, whose cDNA contains an open
reading frame of 477 bp encoding a peptide of 158 amino
acids with a predicted molecular mass of 18 kD [20]. Reg
IV functions as a potent activator of the EGFR/Akt/AP-1
signaling pathway in several types of cancer cells and
increases the expression of Bcl-2, Bcl-xl, and surviving
proteins, related to the inhibition of apoptosis, suggesting
that it may act as a tissue mitogen or play a role in the
cell growth [21]. Additionally, Reg IV has been found to
be colocalized with Ki-67, indicating that it may be
involved in the proliferative process of epithelial cells
[22]. Besides this, it also contributes to liver metastasis
by inducing the expression of matrix metalloproteinase 7
[23]. In recent year, accumulating studies on Reg IV had
reported its presence and overexpression in numerous
cancers. The up-regulation of Reg IV in colorectal aden-
omas was testified by several different research groups
[10,24,25]; Zhang et al. [24] also indicated that Reg IV
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enoma, and its detection might be useful in the early
diagnosis of colorectal adenoma formation. In gastric
carcinogenesis, Zheng et al. [26] detected the increased
expression of Reg IV from gastric intestinal metaplasia to
adenoma, but the decreased expression during the malig-
nant transformation of gastric epithelial cells. These find-
ings revealed that Reg IV expression should be
considered as a good biomarker for gastric precancerous
lesions. In prostate cancer, Hayashi et al. found the
higher serum Reg IV concentration compared with con-
trol individuals, indicating that serum Reg IV represents
a novel biomarker for this disease [15]. In line with these
previous studies, our data in the present study demon-
strated the up-regulation of Reg IV mRNA and protein
in human glioma tissues. Interestingly, we also deter-
mined that the Reg IV mRNA expression was closely cor-
related with its protein expression, suggesting that the
up-regulation of Reg IV in gliomas may be primarily
caused by transcriptional activation. Additionally, its
overexpression was associated with advanced patho-
logical grade and low KPS. These results confirmed the
contribution of Reg IV expression to the aggressive pro-
gression of human gliomas.
Given above intriguing observation correlating Reg IV
up-regulation with advanced tumor progression in
human gliomas, we were further interested in studying a
potential prognostic value of Reg IV for this malignancy.
As the results, overall survival after surgical resection
among glioma patients in Reg IV-high group was poorer
than those in Reg IV-low group. However, there are
some different findings on the relationship between Reg
IV expression and survival of patients with cancer. For
example, Tamura et al. [14] revealed that the positive
Reg IV expression might be independently associated
with a favorable prognosis in patients with advanced
gallbladder carcinoma. In gastric cancer, no statistically
significant prognostic effect of Reg IV was found [25].
These different reports suggest that the contribution of
Reg IV expression to the clinical outcome of patients
may be different according to the type of malignancy.
In conclusion, our data offer the convince evidence for
the first time that Reg IV might accelerate disease pro-
gression and act as a candidate prognostic marker for
human gliomas. Further elucidation on the roles of Reg
IV as tumor promoter in gliomas is worth to be done.Competing interest
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